focus -WSS

focus

author：comprehensive 2025-09-29 01:35:28 - browse：85

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Acelyrin, a rare IPO success, stumbles in its first big test

hotspot

focus

WSS

Hospitals consider fixing cancer drug shortages on their own

Key Senate panel to consider PBM, drug pricing reform package

Long Covid needs a new name — and a new frame

WATCH: Why do bright lights make us see spots?

How medical schools plan to diversify without affirmative action

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

leisure time

focus

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Food makers to regulators: Ultra

DIEP, the 'gold standard' of breast reconstruction, is under threat

Will the IRA bring competition to the biologics market?

Affirmative action in medical school literally saved lives

FDA approves updated Covid vaccines

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Walmart eyes Medicare Advantage provider ChenMed

Heart attack and stroke risk calculators need revising

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

knowledge

Lung cancer screening guidelines updated for cigarette smokers

New Covid vaccine is recommended for everyone 6 months or older

Food makers to regulators: Ultra

Medicare proceeds with plan to claw back hospital funds

After Sarepta trial failure, Duchenne families brace for more debate

Hospitals consider fixing cancer drug shortages on their own

hotspot

focus

Wikipedia

Wikipedia